Drug Type Biosimilar, Fusion protein |
Synonyms 惠尔凝 |
Target |
Mechanism TPO receptor agonists(Thrombopoietin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (07 Jan 2022), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Primary thrombocytopenia | CN | 07 Jan 2022 |